Skip to main content

Minoxidil/progesterone topical and Alcohol/Food Interactions

There are 3 alcohol/food/lifestyle interactions with minoxidil / progesterone topical.

Moderate

Progesterone Topical High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

estrogens/progestogens - fluid retention

Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods. Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid. In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.

References (27)
  1. Leiman G (1972) "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure." Am J Obstet Gynecol, 114, p. 97-102
  2. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  3. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  4. (2001) "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Climara (estradiol)." Berlex Laboratories
  6. (2001) "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories
  7. (2001) "Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals
  8. (2001) "Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals
  9. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  10. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  11. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  12. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  13. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  14. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  15. "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
  16. (2001) "Product Information. Emcyt (estramustine)." Pharmacia and Upjohn
  17. (2001) "Product Information. Megace (megestrol)." Bristol-Myers Squibb
  18. (2001) "Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical
  19. "Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical
  20. (2001) "Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn
  21. "Product Information. Estinyl (ethinyl estradiol)." Schering Corporation
  22. (2001) "Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc
  23. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  24. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  25. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
  26. (2001) "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC
  27. (2006) "Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals
Moderate

Progesterone Topical High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)

Moderate Potential Hazard, Moderate plausibility

progestogens - hyperlipidemia

Some progestogenic agents may elevate plasma LDL levels and/or lower HDL levels, although data have been inconsistent. Patients with preexisting hyperlipidemia may require closer monitoring during progestogen therapy, and adjustments made accordingly in their lipid-lowering regimen.

References (17)
  1. Barnes RB, Roy S, Lobo RA (1985) "Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women." Obstet Gynecol, 66, p. 216-9
  2. Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE (1989) "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception, 39, p. 619-32
  3. Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D (1986) "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet, 24, p. 291-6
  4. Teichmann AT, Wander HE, Cremer P, et al. (1987) "Medroxyprogesterone acetate and lipid metabolic changes." Arzneimittelforschung, 37, p. 573-77
  5. Who Task Force on Long-acting Agents for Fertility Regulation (1986) "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ, 64, p. 587-94
  6. Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV (1993) "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med, 38, p. 207-14
  7. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  8. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  9. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  10. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  11. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  12. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  13. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  14. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  15. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  16. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  17. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories
Minor

Progesterone Topical Obesity

Minor Potential Hazard, Moderate plausibility

progestogens - weight gain

Progestogens can cause weight gain, which may be significant (as is the case with parenteral medroxyprogesterone) and undesirable in obese patients attempting to lose weight.

References (13)
  1. Leiman G (1972) "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure." Am J Obstet Gynecol, 114, p. 97-102
  2. Amatayakul K, Sivasomboon B, Thanangkul O (1980) "A study of the mechanism of weight gain in medroxyprogesterone acetate users." Contraception, 22, p. 605-22
  3. (2001) "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn
  4. (2001) "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn
  5. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
  6. (2001) "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical
  7. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
  8. (2001) "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories
  9. (2001) "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical
  10. (2001) "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories
  11. (2001) "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories
  12. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical
  13. (2001) "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories

Switch to consumer interaction data

Minoxidil/progesterone topical drug interactions

There are 208 drug interactions with minoxidil / progesterone topical.

Minoxidil/progesterone topical disease interactions

There are 11 disease interactions with minoxidil / progesterone topical which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer